Strategies for reduction in duration of antibiotic use in hospitalized patients

Clinical Infectious Diseases

Volumn 52, Issue 10, 2011, Pages 1232-1240

  Hayashi, Yoshiro ^a,b   Paterson, David L ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BIOLOGICAL MARKER; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; FLEROXACIN; GEMIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MIRAXID; PROCALCITONIN; TELITHROMYCIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ACUTE PYELONEPHRITIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; CATHETER COMPLICATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG DOSE COMPARISON; DRUG USE; EPIDEMIC MENINGITIS; HOSPITAL PATIENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG MONITORING; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; HOSPITALIZATION; HUMANS; TIME FACTORS;

EID: 79955367751     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir063     Document Type: Article

References (67)

1. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77. (Pubitemid 46084814)
2. Rice LB. The Maxwell Finland lecture: for the duration-rational antibiotic administration in an Era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis 2008; 46:491-6. (Pubitemid 351263484)
3. Mandell Lionel A, Wunderink Richard G, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72. (Pubitemid 46290553)
4. Malacarne P, Rossi C, Bertolini G. GiVi TIg. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. J Antimicrob Chemother 2004; 54:221-4. (Pubitemid 39028994)
5. Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10:R78.
6. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment Patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210-8.
7. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343-8.
8. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed Solution for Indiscriminate antibiotic Prescription. Am J Respir Crit Care Med 2000; 162:505-11. (Pubitemid 30647191)
9. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator- associated pneumonia. Chest 2004; 125:1791-9. (Pubitemid 38648413)
10. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, doubleblind study. Am J Ther 1999; 6:217-22. (Pubitemid 29342881)
11. Léophonte P, Choutet P, Gaillat J, et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Médecine et Maladies Infectieuses 2002; 32:369-81. (Pubitemid 34763793)
12. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60. (Pubitemid 37153652)
13. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20:555-63. (Pubitemid 38525164)
14. Léophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98:708-20. (Pubitemid 38842773)
15. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54:515-23. (Pubitemid 39177479)
16. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332:1355-360.
17. File TM Jr., Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemi- floxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, doubleblind study. J Antimicrob Chemother 2007; 60:112-20. (Pubitemid 47073284)
18. Chastre J, Wolff M, Fagon J-Y, et al. Comparison of 8 vs 15 Days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98. (Pubitemid 37443289)
19. Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for Four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillinsusceptible streptococci. Clin Infect Dis 1998; 27:1470-4. (Pubitemid 29242423)
20. Gleckman R, Bradley P, Roth R, Hibert D, Pelletier C. Therapy of symptomatic pyelonephritis in women. J Urol 1985; 133:176-8. (Pubitemid 15158397)
21. Stamm WE, McKevitt M, Counts GW. Acute Renal infection in women: treatment with trimethoprim-Sulfamethoxazole or ampicillin for two or six weeks. Ann Intern Med 1987; 106:341.
22. Jernelius H, Zbornik J, Bauer CA. One or three weeks' treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988; 223:469-77.
23. de Gier R, Karperien A, Bouter K, et al. A sequential study of intravenous and oral Fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections. Int J Antimicrob Agents 1995; 6:27-30.
24. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 Days) and trimethoprim-Sulfamethoxazole (14 Days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000; 283:1583-90. (Pubitemid 30161514)
25. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750mg once daily for 5 days versus ciprofloxacin 400mg and/or 500mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007; 23:2637-45. (Pubitemid 350146402)
26. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg Once-daily for five days with ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008; 71:17-22. (Pubitemid 351173271)
27. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120:783-90. (Pubitemid 47313349)
28. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008; 68:1841-54.
29. Guidelines for the management of adults with hospital-acquired, ventilator-associated, healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
30. Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. Surg Infect 2007; 8:589-98.
31. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267-84. (Pubitemid 39458512)
32. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
33. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of Complications: a Statement for healthcare Professionals from the Committee on Rheumatic fever, endocarditis, and Kawasaki disease, Council on Cardiovascular disease in the Young, and the Councils on clinical Cardiology, Stroke, and Cardiovascular surgery and Anesthesia, American Heart Association: Endorsed by the infectious diseases Society of America. Circulation 2005; 111:e394-434.
34. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133-64.
35. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial Cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29:745-58. (Pubitemid 30256361)
36. Nathan N, Borel T, Djibo A, et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet 2005; 366:308-13. (Pubitemid 41019420)
37. Briggs S, Ellis-Pegler R, Roberts S, Thomas M, Woodhouse A. Short course intravenous benzylpenicillin treatment of adults with meningococcal disease. Intern Med J 2004; 34:383-7. (Pubitemid 39093181)
38. Ellis-Pegler R, Galler L, Roberts S, Thomas M, Woodhouse A. Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. Clin Infect Dis 2003; 37:658-62. (Pubitemid 37100805)
39. Rubinstein E. Short antibiotic treatment courses or how short is short? Int J Antimicrob Agents 2007; 30(Suppl 1):76-9.
40. Kyriakidou KG, Rafailidis P, Matthaiou DK, Athanasiou S, Falagas ME. Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin Ther 2008; 30:1859-68.
41. Francioli P, Ruch W, Stamboulian D. Group TIIES. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 Days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406-10. (Pubitemid 26066630)
42. Wilson WR, Thompson RL, Wilkowske CJ, Washington JA 2nd, Giuliani ER, Geraci JE. Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. JAMA 1981; 245:360-3. (Pubitemid 11213002)
43. Tan J, Kaplan S, Terhune C, Hamburger M. Sucessful two-week treatment schedule for penicillin-susceptible Streptococcus viridans endocarditis. Lancet 1971; 298:1340-3.
44. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med 1994; 121:873-6.
45. Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125:969-74. (Pubitemid 26424525)
46. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109:619-24.
47. Fortun J, Navas E, Jesus M-B, et al. Short-Course therapy for right-Side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33:120-5. (Pubitemid 32554513)
48. Torres-TortosaM, de Cueto M, Vergara A, et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cadiz. Eur J Clin Microbiol Infect Dis 1994; 13:559-64. (Pubitemid 24247581)
49. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 Days) and standard (10 Days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-74. (Pubitemid 39037946)
50. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic in- flammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36:941-52.
51. Pfäfflin A, Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009; 393:1473-80.
52. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28:977-83. (Pubitemid 30262065)
53. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and metaanalysis. Lancet Infect Dis 2007; 7:210-7. (Pubitemid 46274517)
54. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007; 50:34-41. (Pubitemid 46907302)
55. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003. (Pubitemid 43982479)
56. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum Procalcitonin and C-Reactive Protein Levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-17. (Pubitemid 38971491)
57. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-7. (Pubitemid 38264177)
58. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93. (Pubitemid 43955248)
59. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9-19. (Pubitemid 46122969)
60. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-Guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168:2000-7.
61. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498-505. (Pubitemid 351442188)
62. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)- guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009; 394:221-6.
63. Hochreiter M, Kohler T, Schweiger A, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009; 13:R83.
64. Kristoffersen KB, Søgaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission-a randomized trial. Clin Microbiol Infect 2009; 15:481-7.
65. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in Ventilator Associated Pneumonia - a randomized study. Eur Respir J 2009; 34:1364-75.
66. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitoninbased guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059-66.
67. Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-74.